Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.110
+0.110 (2.75%)
May 2, 2025, 10:51 AM EDT - Market open
Radiopharm Theranostics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Radiopharm Theranostics stock have an average target of 13.5, with a low estimate of 12 and a high estimate of 15. The average target predicts an increase of 228.47% from the current stock price of 4.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Radiopharm Theranostics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 |
|---|---|---|
| Strong Buy | 1 | 2 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +191.97% | May 1, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +264.96% | Mar 12, 2025 |
Financial Forecast
Revenue This Year
n/a
from 1.96M
Revenue Next Year
21.03M
EPS This Year
-0.03
from -0.12
EPS Next Year
-0.22
from -0.03
Financial currency is AUD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 47.0M | 120.5M | ||
| Avg | n/a | 21.0M | 68.6M | ||
| Low | n/a | n/a | 36.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 472.7% | ||
| Avg | - | - | 226.3% | ||
| Low | - | - | 73.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.02 | -0.02 | - | ||
| Avg | -0.03 | -0.22 | -0.30 | ||
| Low | -0.03 | -0.59 | -0.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.